Hallucinations. Sleep paralysis. Excessive daytime sleepiness. Jenny Lee-Gilmore was diagnosed with Type 1 narcolepsy at 21 — ...

Model Lee Hyun-yi confessed that she was diagnosed with narcolepsy, a rare and intractable disease.According to the Health ...

Narcolepsy is a sleep disorder that affects the brain ability to regulate sleep-wake cycles and it can present unique challenges for adolescents Teenagers with narcolepsy experience symptoms like exce ...

Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven ...

017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with narcolepsy. AXS-12 is an investigational highly selective potent norepinephrine reuptake ...

Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges ...

NEWARK, Del, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The Narcolepsy Treatment Market 2024 to 2034 is expected to experience substantial growth, with the market size projected to expand from USD 5,301.6 ...

I feel myself weightless, but like I literally cannot move. I thought narcolepsy was what we saw on TV. I had no basis for understanding it, and I never done my own research to actually figure out ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is ...

Since collecting the exclusive U.S. rights and data on the drug from Pfizer in 2020, Asxome has been busy building on its two earlier studies of AXS-12 in narcolepsy. Now, with fresh phase 3 data ...

ENCORE was a multi-center, two-period Phase 3 trial evaluating the long-term efficacy and safety of AXS-12 in patients with narcolepsy with cataplexy, consisting of a 6-month open-label AXS-12 ...